Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Elicio Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ELTX alerts

About Peter DeMuth

Elicio Therapeutics, Inc. reported in an 8-K filed June 2, 2023 that Peter DeMuth was appointed Chief Scientific Officer, effective June 1, 2023. The proxy statement of Elicio Therapeutics, Inc. reports total compensation of $866,671 for Peter DeMuth in fiscal 2024, including a base salary of $460,000. Disclosed compensation is on record for 2 fiscal years. Elicio Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Elicio Therapeutics, Inc. includes Robert Connelly (CEO, Chief Accounting Officer and Board Member), Julian Adams (Chairman), Julian Adams, Ph.D. (Chairman and Board Member) and 7 others.

“At the effective time of the Merger, the Company's board of directors (and its committees) and executive officers were reconstituted to include the following directors and executive officers”
Elicio Therapeutics, Inc. Form 8-K, filed June 2, 2023 · Read the filing

Affiliation history

Company network

Leadership on record at Elicio Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2024 Elicio Therapeutics, Inc. (ELTX) $460,000 $866,671
2023 Elicio Therapeutics, Inc. (ELTX) $364,229 $502,636

Recent activity